| Authors: |
Matza LS; PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA., Rowen D; Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, England, UK. Electronic address: d.rowen@sheffield.ac.uk., Chandler F; Duchenne UK, London, England, UK., Dalziel K; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia., Ghabri S; French National Authority for Health (Haute Autorité de Santé), Saint Denis, France., Law EH; HTA, Value & Evidence Strategy, Pfizer Inc, New York, NY, USA., Prosser LA; Susan B. Meister Child Health Evaluation & Research Center, Department of Pediatrics, University of Michigan, Ann Harbor, MI, USA., Rivero-Arias O; National Perinatal Epidemiology Unit, Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, England, UK., Shah K; Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, England, UK; National Institute for Health and Care Excellence, London, England, UK., Stolk E; EuroQol Research Foundation, Rotterdam, The Netherlands; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., Wolff J; Emeritus, Blavatnik School of Government, University of Oxford, Oxford, England, UK., Devlin N; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. |
